Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cervus and cucumis polypeptide is a traditional Chinese medicine injection composed of bioactive peptides extracted from Sika deer bone (Cervus nippon Temminck) and sweet melon seeds (Cucumis melo L), typically mixed at a 2:1 ratio. It is used primarily in China for the treatment of rheumatoid arthritis, bone fractures, and related conditions. The preparation contains more than 3 mg/mL total peptide content. Its mechanism of action involves inhibition of Receptor activator of nuclear factor kappa-B ligand signaling pathway (RANKL) induced osteoclastogenesis signaling pathways in osteoclast precursor cells, thereby reducing inflammation, preventing bone erosion, promoting fracture healing, and modulating immune responses. Studies suggest it enhances anti-inflammatory factor secretion (such as HGF, PGE2, TSG6) when combined with umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cervus and cucumis polypeptide.